1268-PUB: The Relationship of Time-in-Range (TIR) and HbA1c and the Factors That Contribute to a Better TIR

Background: HbA1c, the current gold standard treatment target for patients with diabetes, cannot reveal the glucose fluctuation. Therefore, new metrics need to be incorporated with HbA1c to better understand the dynamic nature of glucose. As the use of continuous glucose monitoring (CGM) increases, there is a need to better understand key metrics of time in range 70-180 mg/dL (TIR). Methods: Patients with T2DM underwent a 48-h to 72-h CGM were included and divided into two groups: low TIR group (LTIR, TIR 0.05) between the LTIR group (n=11) and the HTIR group (n=99). HbA1c (7.96±1.08% vs. 6.69±1.23%, p =0.002) and TAR (61.59±7.88% vs. 90.59±7.73%, p70%.